273P - Cisplatin in combination with pemetrexed in the treatment of patients for advanced malignant peritoneal mesothelioma: Retrospective study of 21 cases

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Oesophageal Cancer
Gastrointestinal Cancers
Presenter kanemura Shingo
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors K. Shingo, K. Kuribayashi, E. Fujimoto, Y. Koda, Y. Negi, E. Shibata, T. Otsuki, K. Mikami, T. Nakano
  • Respiratory Medicine, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP

Abstract

Background

Malignant peritoneal mesothelioma (PM) is a relatively rare disease accounting for 10% of all mesotheliomas that occur in the mesothelial cells of the pleura, peritoneum, pericardium, and tunica vaginalis testis, and its prognosis is poor. A standard therapy for malignant PM has not been established. Conventional therapies are employed for malignant PM in clinical settings; however, the treatment outcomes are unknown. This was a retrospective study to evaluate the effects of primary chemotherapy of CDDP + PEM on patients with PM.

Methods

Twenty-one subjects who were pathologically and definitively diagnosed with PM and received 2 or more cycles of first-line combination chemotherapy of CDDP + PEM were included in this study. Treatment outcome was assessed using CT images based on RECIST. FDG-PET images obtained before and after the treatment were used for cases that were difficult to assess based on CT findings.

Results

The median age of the patients was 60.6 years (32–76 years), and 13 men and 8 women were included. Histological types included 20 epithelial and 1 biphasic types while clinical conditions included 5 cases of ascites retention, 6 mass forming, and 10 mixed types. In assessment of tumor reduction effects, 2, 9, and 5 subjects achieved a CR (10%), PR (42%), and a SD (24%), respectively, and PFS and MST were 10.1 and 16.7 months, respectively. Epithelial and ascites retention predicted favorable outcome of chemotherapy.

Conclusions

While PM is generally considered an extremely treatment-resistant malignant tumor, classical first-line therapy of CDDP + PEM allowed us to demonstrate a response rate of 52% and PFS of 10 months or longer. Although this was a retrospective study, these results are more favorable than those observed for patients with primary mesothelioma in the pleura. Therefore, first-line systemic chemotherapy of CDDP + PEM can be considered effective for patients with PM.

Clinical trial indentification

Legal entity responsible for the study

Hyogo College of Medicine

Funding

Hyogo College of Medicine

Disclosure

All authors have declared no conflicts of interest.